Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Sana Biotechnology (NASDAQ: SANA) will present at the 44th Annual J.P. Morgan Healthcare Conference with a live webcast on Wednesday, January 14, 2026 at 9:45 a.m. PT.
The presentation will include a business overview and update delivered by Steve Harr, president and chief executive officer. The webcast and a replay will be available on Sana's Investor Relations website, with the replay accessible for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA) reported that Nature Biotechnology published preclinical data showing systemic, in vivo gene editing of human hematopoietic stem and progenitor cells (HSCs) in murine models using Sana’s fusogen virus-like particle (VLP) platform (DOI: 10.1038/s41587-025-02915-2) on Dec 8, 2025. Results demonstrate potent, cell-specific editing in long-term HSCs, editing at two hemoglobinopathy-relevant loci including fetal hemoglobin, and avoidance of off-target delivery to hepatocytes. Sana said the fusogen platform now expands beyond T cells to HSCs and is being used to develop SG293 (a CD8-targeted fusosome to make CD19 CAR T cells in vivo) with an IND filing expected as early as 2027.
Sana Biotechnology (NASDAQ: SANA) will webcast presentations at two investor conferences in December 2025 featuring a business overview and update by Steve Harr, President and CEO.
Sana will present at Citi’s 2025 Global Healthcare Conference on Dec 2, 2025 at 2:30 p.m. ET and at the 8th Annual Evercore Healthcare Conference on Dec 3, 2025 at 2:35 p.m. ET. Live webcasts and replays will be available on Sana’s Investor Relations page at https://sana.com/, with each replay accessible for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA) reported Q3 2025 results and strategic reprioritization focused on SC451 (HIP-modified iPSC-derived islet cells for type 1 diabetes) and SG293 (next‑generation in vivo CAR T).
Key developments: NEJM published positive 12-week data for UP421 showing transplanted HIP-modified islet cells survived, evaded immune detection, and produced C-peptide without immunosuppression. Sana expects to file an IND for SC451 as early as 2026 and an IND for SG293 as early as 2027. The company suspended enrollment and internal investment in its allogeneic CAR T programs SC291 and SC262 to focus resources.
Financials: Cash $153.1M at Sept 30, 2025; raised additional equity in Q3–Q4 2025 and expects a cash runway into late 2026. Non-cash impairment of $44.6M recorded in 2025.
Sana Biotechnology (NASDAQ: SANA) will present at the TD Cowen Immunology & Inflammation Summit on Wednesday, November 12, 2025 at 1:30 p.m. ET. The presentation, given by Steve Harr, President and CEO, will provide a business overview and company update.
The presentation will be webcast and available on Sana's Investor Relations website at https://sana.com/. A replay will be posted at the same location for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cell therapies, has announced its participation in four major investor conferences this September 2025.
The company will present business overviews and updates at:
- Citi's Biopharma Back-to-School Conference on September 2 at 3:15 PM ET
- Wells Fargo Healthcare Conference on September 4 at 8:00 AM ET
- Morgan Stanley Global Healthcare Conference on September 8 at 11:30 AM ET
- HC Wainwright Global Investment Conference on September 9 at 9:30 AM ET
All presentations will be available via webcast on Sana's Investor Relations website, with replays accessible for 30 days after each event.
Sana Biotechnology (NASDAQ: SANA) has successfully closed the full exercise of underwriters' option to purchase additional shares, following its previously announced public offering. The company sold 3,358,208 shares at $3.35 per share, generating total gross proceeds of approximately $86.3 million including the main offering.
The offering was managed by joint book-runners Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen. The transaction was conducted under a previously filed and SEC-approved Registration Statement on Form S-3.
Sana Biotechnology (NASDAQ: SANA) reported significant progress in Q2 2025, highlighted by positive 6-month clinical results for their type 1 diabetes treatment using hypoimmune-modified pancreatic islet cells. The study, published in the New England Journal of Medicine, demonstrated successful cell transplantation without immunosuppression.
The company strengthened its financial position by raising $105 million through ATM offerings and equity financing in July-August 2025. Q2 ended with $72.7 million in cash, with a pro forma position of $177.2 million. The company expects its cash runway to extend into H2 2026.
Key pipeline developments include plans to file INDs for SC451 and SG299 in 2026, ongoing enrollment in the GLEAM trial (SC291) for autoimmune diseases and VIVID trial (SC262) for B-cell malignancies, with clinical data expected in 2025.
Harbinger Health announced the appointment of Ajit Singh, Ph.D. as its new CEO and CEO-Partner of Flagship Pioneering. Singh, who has served on Harbinger's board since 2024, brings extensive diagnostics industry experience, particularly from his tenure at Siemens and leadership in oncology diagnostics companies.
Current CEO Stephen Hahn, M.D. will transition to CEO Emeritus and Special Advisor while maintaining his position on the Board of Directors. The leadership change comes as Harbinger advances its platform for early cancer detection using blood-based tests that analyze proprietary methylation patterns of cell-free ctDNA.
The company recently presented data showing promising results in detecting multiple high-incidence, high-mortality cancers related to obesity, along with platform innovations to enhance cancer signal detection.
Sana Biotechnology (NASDAQ: SANA) has announced the pricing of its public offering, consisting of 20,895,522 shares of common stock at $3.35 per share and pre-funded warrants to purchase 1,492,537 shares at $3.3499 per warrant. The company expects to raise approximately $75.0 million in gross proceeds before deducting expenses.
The offering includes a 30-day option for underwriters to purchase up to 3,358,208 additional shares. Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen are serving as joint book-running managers. The offering is expected to close around August 8, 2025, subject to customary conditions.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
